The spread of mcr-1 in human and veterinary medicine has jeopardized the use of 20 polymyxins, the last-resort antibiotics against life-threatening multidrug-resistant 21 Gram-negative bacteria. As a lipid-modified gene, whether mcr-1 brings proteomic and 22 metabolomic changes in the bacteria and affects the corresponding metabolic pathway 23 is largely unknown. Herein, we used label-free quantitative proteomics and untargeted 24 metabolomics to profile comprehensive proteome and metabolome characteristics of 25 mcr-1-mediated colistin-resistant and -sensitive Escherichia coli and further insight the 26 resistant mechanism of colistin. We identified large sets of differential expression 27 proteins and metabolites that contributed to mcr-1-mediated antibiotic resistance 28 predominantly in the different growth conditions with and without colistin. mcr-1 could 29 cause the down-regulated expression of most proteins to adapt drug pressure. Pathway 30 analysis showed that metabolic process was significantly affected, mainly related to 31 glycerophospholipid metabolism, thiamine metabolism, and lipopolysaccharide 32 biosynthesis. The substrate phosphatidylethanolamine for mcr-1 to mediate colistin 33 resistance is accumulated in colistin-resistant E. coli. Notably, mcr-1 can not only cause 34 the phosphoethanolamine modification of bacterial cell membrane lipid A, but also 35 affect the biosynthesis and transport of lipoprotein in colistin resistance through 36 disturbing the expression of efflux pump proteins involved in cationic antibacterial 37 peptide resistance pathway. Overall, the disturbed glycerophospholipid metabolism, 38 lipopolysaccharide biosynthesis and the accumulation of the substrate 39 phosphatidylethanolamine is closely related with mcr-1-mediated colistin resistance 3 40
Introduction
and pentose phosphate pathway was up-regulated, indicating an increase in energy 328 metabolism to accommodate drug stress (Fig 3) . 329 Untargeted metabolomic analysis 330 Untargeted metabolomic profiling of colistin-resistant E. coli DH5α (pUC19-mcr-331 1) and colistin-sensitive E. coli DH5α (pUC19) strains under different culture 332 conditions was studied to obtain their metabolic characteristics. First, PCA was used to 333 investigate the metabolomic profile of the two strains cultured in different Fig 4B and 4D , respectively. A total of 67 differential metabolites were 343 simultaneously found in different drug culture conditions, of which 49 metabolites were 344 selected in ESI + mode, 18 metabolites were found in ESImode (Table 1) . Among all 345 the identified metabolites separated on C 18 column, 24 features (10 up-regulated and 1 346 down-regulated) were found in ESI + mode and 13 features (10 up-regulated and 3 347 down-regulated) were selected in ESImode, respectively. Then we analyzed the 348 metabolites separated on HILIC column. A total of 38 compounds (18 up-regulated and 349 20 down-regulated) were identified in ESI + mode and 5 features (4 up-regulated and 1 350 down-regulated) were selected in ESImode, respectively (Table 1) . For QC purposes, 351 several reference standards were added to verify the reliability of the metabolomics 352 analysis. The average error of calculated mass was below 10 ppm, the retention time 353 was nearly identical, and the RSD of the peak area in three batches (different extracts) 354 was 3.52%-6.24% (Table S7) .
355
Enrichment and metabolic pathway analysis 356 Heatmap presentation of all identified intracellular differential metabolites from 357 colistin culture group (CST0, CST0.5 and CST1) was shown in Fig 5A. To facilitate 358 access to metabolic pathway analysis, altered metabolites from the merged data set were 359 mapped to KEGG and obtained the disturbed metabolic pathway using MetaboAnalyst 360 3.0. Metabolite set enrichment analysis showed that pantothenate and CoA biosynthesis, 361 glycerolipid metabolism, phosphatidylethanolamine biosynthesis were contributed to 362 mcr-1 mediated bacterial metabolism ( Fig 5B) . Then we carried out the metabolic 363 pathway analysis and found that polyketide sugar unit biosynthesis, 364 glycerophospholipid metabolism, and lysine biosynthesis were significantly enriched 365 for all the identified differential metabolites ( Fig 5C) . Interestingly, protein-metabolite 366 interaction analysis of the disturbed glycerophospholipid metabolism in mcr-1-367 mediated colistin resistance by the integration of proteomics and metabolomics found 368 that a high number of differential metabolites including PE (14:1(9Z)/16:1(9Z)), GPEtn 369 (18:1(9Z)/0:0), LysoPE (0:0/15:0), GPEtn (18:1(9Z)/0:0), PE (16:1(9Z)/18:1(11Z)), PE 370 (18:1(11Z)/17:0), PE (22:4(7Z,10Z,13Z,16Z)/P-18:0), PGP (16:1(9Z)/12:0), sn-371 glycerol-1-phosphate, 1-acyl-sn-glycero-3-phosphoglycerol (N-C14:1), 1-acyl-sn-372 glycero-3-phosphoglycerol (N-C16:1) involved in glycerophospholipid metabolism 373 were up-regulated in the colistin-resistant E. coli DH5α (pUC19-mcr-1) strains 374 compared with that in the colistin-sensitive E. coli DH5α (pUC19) strains ( Fig 5D) . 377 colistin resistance was that the inner membrane protein MCR-1 was chemically 378 modified as a form of PEA on the lipid A group of bacterial LPS [27] [28] [29] . As a lipid-379 modified gene, whether mcr-1 brings comprehensive proteomic and metabolomic 380 changes in the bacteria and affects the corresponding metabolic pathway is largely 381 unknown. This study is the first to investigate the comprehensive proteomic and conditions. In addition, metabolite expression analysis found that the metabolites 403 involved in glycerophospholipid metabolism were up-regulated due to the insertion of 404 mcr-1. Remarkably, the substrate phosphatidylethanolamine (Kegg ID: C00350) for 405 mcr-1 to mediate colistin resistance was investigated as the differential metabolites and 406 its expression in different colistin selection pressure (CST0, CST0.5, and CST1) were Table 1 Putative differential metabolites identified in colistin-resistant E. coli DH5α (pUC19-mcr-1) under three different drug culture 640 conditions. y c c X y d c H y q 
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